ClinicalTrials.gg
RecruitingNCT07007208Locus-TauUpdated Jul 17, 2026

Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk

A Phase 2 interventional study of a positon emission tomography (PET) exam and MRI Contrast in Alzheimer Disease, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
60 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Alzheimer Disease by University Hospital, Toulouse — 4 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · University Hospital, Toulouse.

Planned enrollment
8th of 14
100 · median 120
Started
2026
with 1 other
Phase 2
2 of 17
1 open now
Registered
16th of 17
by date

Among the 17 studies in Alzheimer Disease by University Hospital, Toulouse, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 16th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 17 studies in Alzheimer Disease by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Alzheimer Disease by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is characterized by a long-lasting silent phase. Among initial events, emergence of tau pathology in locus coeruleus (LC) brainstem nucleus, well before the one observed in medial temporal cortex, is highly relevant. LC integrity and function can be assessed in vivo with MRI and pupil measures. The current research proposes to evaluate these LC markers in an aged healthy cohort (n=100, with half APOE4 positive) and to relate these markers with cerebral tau pathology, AD risk and cognitive function.

Read the detailed description

Early tau pathology in the LC may induce dysfunction of the LC-NA system, contribute to initial cognitive decline and possibly be predictive of future AD occurrence. The present project has the following objectives: 1) to relate different biomarkers of LC function measured in vivo with AD risk and future AD occurrence, in order to evaluate their relevance for earliest AD diagnosis, 2) to investigate how LC biomarkers can account for underlying brain tau pathology in asymptomatic older individuals; a related objective will be to validate LC biomarkers as reliable proxies of tau pathology occurrence, and 3) to study the link between LC biomarkers and cognitive performance.

To complete these objectives, the project will evaluate, in healthy older volunteers from the INSPIRE-T cohort (n=100, > 60 years old), biomarkers of LC neuronal integrity, LC-forebrain connectivity, and LC tonic and phasic activity. Additionally, a positon emission tomography (PET) exam will be conducted using tau-specific tracer. Detailed cognitive assessment will also be performed, including assessment of a priori NA-dependent and NA-independent cognitive functions. In the studied cohort (n = 100), half volunteers will be recruited based on genetic AD risk (APOE4 positive) and the other half based on the absence of risk (APOE4 negative).

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • PET
  • MRI
  • occulometry
  • locus coeruleus
  • Alzheimer disease
04

Who can participate

Ages eligible
60 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant in the INSPIRE-T cohort
  • Normal cognitive assessment
  • score ≥ 27 out of 30 (Mini-Mental State Examination)
  • Normal visual abilities (in corrected or uncorrected vision)
  • Normal motor skills

Exclusion criteria

Exclusion Criteria:

  • Subjects with a to MRI exam
  • Subjects with a known allergic reaction to the PET radiopharmaceutical ([18F] Flortaucipir) or any of its
  • Subjects with an ophthalmological pathology making oculometric measurements difficult
  • Subjects with a neurodegenerative condition or a history of cerebral ischemia
  • Subjects with a psychiatric disorder and a PHQ-9 score > 10 or under treatment with NRI
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    experimental arm

    TEP exam, MRI exam, oculometry assessment and cognitive tasks

    Drug: a positon emission tomography (PET) exam · Other: MRI Contrast · Other: oculometry assessment · Other: cognitive exams

Interventions

  • Druga positon emission tomography (PET) exam

    TEP exam using tau-specific tracer ( Flortaucipir, unique dose 360 MBq)

  • OtherMRI Contrast

    Data acquisition will include different sequences (anatomical MRI, resting fMRI). The MRI sequences performed will be anatomical imaging (i.e. T1 imaging, FLAIR), a diffusion sequence, a neuromelanin-sensitive sequence and functional imaging at rest (i.e. "the resting state", which allows the functional connectivity within the so-called "default" network to be assessed).

  • Otheroculometry assessment

    Pupillometry and oculometry will be conducted using an EyeBrain medical device (class IIa). Several cognitive tasks will be submitted to the participant, during which the same measurements will be taken. Different stimuli will be presented on the computer screen (visual scenes, text, geometric shapes) during the eye tracking measurement, and an instruction (cognitive task, such as semantic categorization, free exploration of the gaze, reading, saccade execution) will be associated with each type of stimulus. The successive stimuli will be spaced more than 7 secondes apart in order to allow the pupillary response to the first stimulus to be recorded and then to return to the basal diameter before presentation of the next stimulus.

  • Othercognitive exams

    Cognitive measures will be acquired during an evaluation session through 6 interactive cognitive exercises. These exercises are developed using tools offered by Covirtua Healthcare.

06

What researchers measure

Primary outcomes

  1. diagnostic capabilities of Locus Coeruleus biomarkers for a positive PET-Tau exam

    The diagnostic capabilities (sensitivity, specificity and AUC) of each of the elements of oculometry (pupillary response, number, latency and amplitude of ocular saccades), functional MRI (LC-hippocampus and LC-prefrontal cortex) and structural MRI (LC intensity) for a positive PET-Tau examination

    Time frame: 24 monnths

Secondary outcomes

  1. diagnostic capabilities of Locus Coeruleus biomarkers for a positive PET-Tau exam for the APOe4- groups

    The diagnostic capabilities (sensitivity, specificity and AUC) of each of the elements of oculometry (pupillary response, number, latency and amplitude of ocular saccades), functional MRI (LC-hippocampus and LC-prefrontal cortex) and structural MRI (LC intensity) for a positive PET-Tau examination in APOe4- patients

    Time frame: 24 months

  2. diagnostic capabilities of Locus Coeruleus biomarkers for a positive PET-Tau exam for the APOe4+ groups

    The diagnostic capabilities (sensitivity, specificity and AUC) of each of the elements of oculometry (pupillary response, number, latency and amplitude of ocular saccades), functional MRI (LC-hippocampus and LC-prefrontal cortex) and structural MRI (LC intensity) for a positive PET-Tau examination in APOe4+ patients

    Time frame: 24 months

  3. The relationship between different LC biomarkers

    this will be evaluated by correlation and regression. The correlations will be performed both together and separately in the APOe4 status. The impact will be assessed by linear and logistic regression and will also take into account age, gender, and education level.

    Time frame: 24 months

  4. The link between PET Tau uptake and PET-estimated perfusion changes

    this will be assessed by the correlation between variations expressed in absolute value or as a proportion of the baseline value and Tau marking, and by regression at 12 and 24 months. The correlations will be performed both together and separately in the APOe4 status, and the regression will also take into account age, gender, and education level.

    Time frame: 24 months

  5. The link between PET Tau uptake in oculometry

    this will be assessed by the correlation between variations expressed in absolute value or as a proportion of the baseline value and Tau marking, and by regression. The correlations will be performed both together and separately in the APOe4 status, and the regression will also take into account age, gender, and education level.

    Time frame: 24 months

  6. The link between PET Tau uptake in the structural (neuromelanin) and functional integrity of the LC by MRI

    this will be assessed by correlating variations expressed as absolute values or as a proportion of the baseline value with PET Tau, and by regression at 12 and 24 months.

    Time frame: 24 months

  7. The link between variations in pupillometry

    this will be assessed by the correlation between variations expressed in absolute value or as a proportion of the baseline value, and by regression at 12 and 24 months.. The correlations will be performed both together and separately in the APOe4 carrier and non-carrier groups, and the regression will also take into account age, gender, and education level.

    Time frame: 24 months

  8. The link between variations in occulometry

    this will be assessed by the correlation between variations expressed in absolute value or as a proportion of the baseline value, and by regression at 12 and 24 months. The correlations will be performed both together and separately in the APOe4 carrier and non-carrier groups, and the regression will also take into account age, gender, and education level, at 12 and 24 months

    Time frame: 24 months

  9. The link between variations in the structural (neuromelanin) and functional integrity of the LC by MRI

    this will be evaluated by correlation between variations expressed as absolute values or as a proportion of the baseline value and by regression at 12 and 24 months

    Time frame: 24 months

  10. The relationship between the various LC biomarkers (PET, MRI, pupillometry) and participants' cognitive performance

    this will be assessed both at inclusion and at 12 and 24 months, using regressions that take into account age, gender, level of education and APOe4 status.

    Time frame: 24 months

  11. comparison between APOe4+ and APOe4-: Structural (neuromelanin) and functional integrity of the LC by MRI

    this Will be assessed both at inclusion, at 12 months, and at 24 months, through regressions that will take into account age, gender, and education level.

    Time frame: 24 months

  12. comparison between APOe4+ and APOe4: Cognitive performance

    this Will be assessed both at inclusion, at 12 months, and at 24 months, through regressions that will take into account age, gender, and education level.

    Time frame: 24 months

  13. comparison between APOe4+ and APOe4-: Pupillometry and oculometry

    this Will be assessed both at inclusion, at 12 months, and at 24 months, through regressions that will take into account age, gender, and education level.

    Time frame: 24 months

  14. The reliability of the amplitude of the phasic pupil response during completion of cognitive tasks

    This will be validated by intraclass correlation between baseline value and value at one month (test-retest) in a subgroup of 30 participants.

    Time frame: 24 months

  15. The reliability of the latency of saccadic eye movements during completion of cognitive tasks

    This will be validated by intraclass correlation between baseline value and value at one month (test-retest) in a subgroup of 30 participants.

    Time frame: 24 months

  16. The reliability of the amplitude of saccadic eye movements during completion of cognitive tasks

    This will be validated by intraclass correlation between baseline value and value at one month (test-retest) in a subgroup of 30 participants.

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Toulouse
    Toulouse, 31059, France
    Recruiting
    • Payoux Pierre, MD · Contactpayoux.p@chu-toulouse.fr · +33 (0)5 62 74 61 69
    • Delrieu Julien, MD · Contactdelrieu.j@chu-toulouse.fr · +33 (0)5 61 77 70 58
    • Payoux Pierre, MD · Principal investigator
    • Delrieu Julien, MD · Principal investigator
    • GIROUD Marine · Sub investigator
    • SASTRE Nathalie · Sub investigator
    • HITZEL Anne · Sub investigator
    • ANGIONI Davide · Sub investigator
    • ABELLAN VAN KAN Gabor · Sub investigator
    • OUSSET Jean-Pierre · Sub investigator
    • FAISANT Catherine · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 35 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2025
First posted
Jun 5, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jan 31, 2029
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007208
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Feb 2, 2026
Primary completion
Jan 31, 2029 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

PAYOUX P Pierre, MD
Contact
payoux.p@chu-toulouse.fr
+33 (0)562746169
DELRIEU J Julien, MD
Contact
dlerieu.j@chu-toulouse.fr
+33 (0)5 61 77 70 58

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion